Though a trial may yield positive NMB in conventional VOI analysis owing to expected cost savings, some clinical outcomes might be unfavorable. To better inform priorities, VOI studies should include disaggregated outcomes alongside aggregated NMB.
Pei et al. (Fri,) studied this question.